O'Brien Institute, Fitzroy, Victoria, Australia.
Heart Lung Circ. 2011 Mar;20(3):173-9. doi: 10.1016/j.hlc.2010.06.661. Epub 2010 Jul 22.
Heart failure affects more than 10% of the Australian population over age 65, and the ageing population will ensure continued growth of this significant problem. There are various treatment options available, but the growing field of regenerative therapy offers promise to restore or replace tissue lost in those with either congenital or acquired cardiac defects. Stem cells have many potential properties, but they need multiple discussed qualities to succeed in this field such as ease of harvest and multiplication, and most importantly minimal ethical concerns. There are multiple cell types available and one of the challenges will be to find the most appropriate cell type for cardiac regeneration. Cardiac tissue engineering is being explored using both in vitro and in vivo techniques. In vitro methods are primarily limited in terms of the vascularisation and size of the construct. In vivo engineered constructs overcome these limitations in early models, but they are still not ready for human trials. This review aims to provide the reader with an outline of the cell-based and tissue engineering therapies currently being used and developed for cardiac regeneration, as well as some insight into the potential problems that may hamper its progress in the future.
心力衰竭影响超过 10%的澳大利亚人口年龄超过 65 岁,并且人口老龄化将确保这个重大问题的持续增长。有各种治疗选择,但不断发展的再生治疗领域有望恢复或替换那些患有先天性或获得性心脏缺陷的组织。干细胞具有许多潜在的特性,但它们需要多个讨论的质量在这个领域取得成功,如易于收获和繁殖,最重要的是最小的伦理问题。有多种细胞类型可供选择,其中一个挑战将是找到最适合心脏再生的细胞类型。心脏组织工程正在使用体外和体内技术进行探索。体外方法主要在血管化和构建体的大小方面受到限制。体内工程构建体克服了早期模型中的这些限制,但它们还没有准备好进行人体试验。本综述旨在为读者提供当前用于心脏再生的基于细胞和组织工程疗法的概述,以及对可能阻碍其未来发展的潜在问题的一些见解。